{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:59:39Z","timestamp":1787759979465,"version":"build-2784847793"},"reference-count":56,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to explore patient preference for attributes of calcitonin gene\u2010related peptide (CGRP) inhibitors for the preventive treatment of migraine and to describe differences in treatment preferences between patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CGRP inhibitors are a novel class of migraine drugs specifically developed for the preventive treatment of migraine. Clinicians should understand patient preferences for CGRP inhibitors to inform and support prescribing choices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with migraine in the US and Germany were recruited to participate in an online discrete choice experiment (DCE) survey, which presented hypothetical treatment choices using five attributes: mode of administration, side effects, migraine frequency, migraine severity, and consistency of treatment effectiveness. Attribute selection was informed by a literature review and semi\u2010structured patient interviews (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a035), and evaluated using patient cognitive debriefing interviews (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 680 who consented to participate, 506 participants completed the survey and were included in the study (US\u00a0=\u00a0257; Germany\u00a0=\u00a0249). Overall, participants placed highest importance (preference weight, beta\u00a0=\u00a01.65,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) on the treatment's ability to reduce the severity of migraine (mild vs. unchanged severity), followed by consistent treatment effectiveness (beta\u00a0=\u00a01.13,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and higher chance of reduced migraine frequency (beta\u00a0=\u00a01.00,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Participants preferred an oral tablet every other day (beta\u00a0=\u00a01.00,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) over quarterly infusion, quarterly injections (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.019), or monthly injection (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Preference for all treatment attributes were heterogeneous, and the subgroup analyses found that participants na\u00efve to CGRP monoclonal antibody treatments had a stronger preference for oral therapy compared to those with such experience (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.006).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this DCE assessing CGRP inhibitors attributes, the main driver of patient choice was treatment effectiveness, specifically reduced migraine severity, and consistent treatment effectiveness. Further, patients exhibited an overall preference for an oral tablet every other day over injectables. Patients' experience with previous treatments informs the value they place on treatment characteristics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14386","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T09:43:02Z","timestamp":1662025382000},"page":"1187-1197","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A stated preference survey to explore patient preferences for novel preventive migraine treatments"],"prefix":"10.1111","volume":"62","author":[{"given":"Lena T.","family":"Hubig","sequence":"first","affiliation":[{"name":"Acaster Lloyd Consulting Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Smith","sequence":"additional","affiliation":[{"name":"StudyMetrix LLC  St. Peters Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gin Nie","family":"Chua","sequence":"additional","affiliation":[{"name":"Acaster Lloyd Consulting Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Acaster Lloyd Consulting Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Powell","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Johnston","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Harris","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals Inc  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"L'Italien","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals Inc  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Coric","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals Inc  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu Hing","family":"Lo","sequence":"additional","affiliation":[{"name":"Acaster Lloyd Consulting Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32160-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"e_1_2_10_5_1","article-title":"Impact and burden of episodic, acute migraine: a patient experience study","volume":"60","author":"Shrewsbury SB","year":"2020","journal-title":"Headache Conference: 62nd Annual Scientific Meeting American Headache Society"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1043265"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_2_10_8_1","volume-title":"Vyepti (eptinezumab\u2010jjmr)","author":"Lundbeck Seattle","year":"2020"},{"key":"e_1_2_10_9_1","volume-title":"Aimovig (erenumab\u2010aooe)","author":"Amgen Inc & Novartis AG","year":"2018"},{"key":"e_1_2_10_10_1","volume-title":"AJOVY (fremanezumab)","author":"Teva Pharmaceuticals USA Inc","year":"2018"},{"key":"e_1_2_10_11_1","volume-title":"Emgality (galcanezumab\u2010gnlm)","author":"Eli Lilly and Company","year":"2019"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13956"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01102-9"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13951"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13498"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.02.019"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0813-3"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_2_10_20_1","article-title":"Understanding the patient experience and disease burden of migraine: a qualitative interview study. The International Headache Congress\u2014IHS and EHF joint congress 2021: late breaking abstracts","volume":"22","author":"Gallop K","year":"2021","journal-title":"J Headache Pain"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"e_1_2_10_22_1","article-title":"The migraine interictal burden scale (MIBS): results of a population\u2010based validation study","volume":"47","author":"Buse DC","year":"2007","journal-title":"Headache Conference: 49th Annual Scientific Meeting American Headache Society"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"e_1_2_10_24_1","article-title":"Development and validation of the migraine interictal burden scale (MIBS): a self\u2010administered instrument for measuring the burden of migraine between attacks","volume":"68","author":"Buse DC","year":"2007","journal-title":"Neurology"},{"key":"e_1_2_10_25_1","unstructured":"ChoiceMetrics.Ngene 1.2 USER MANUAL & REFERENCE GUIDE The Cutting Edge in Experimental Design;2018."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0734-2"},{"key":"e_1_2_10_28_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2021"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocm.2019.100170"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00133443"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-010-9276-0_9"},{"key":"e_1_2_10_32_1","first-page":"105","volume-title":"Frontiers in Econometrics","author":"McFadden D","year":"1974"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022558715350"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trd.2010.04.008"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.1992.10475842"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"issue":"2","key":"e_1_2_10_37_1","first-page":"84","article-title":"Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis","volume":"9","author":"Louder AM","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_10_38_1","first-page":"408","article-title":"Patient preferences associated with therapies for psoriatic arthritis: a conjoint analysis","volume":"11","author":"Xu Y","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13414"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13994"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01151-0"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419888222"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.06.002"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418776017"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trb.2009.12.012"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-0954-6"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.192492"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01263.x"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007646.x"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30293-9"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01941.x"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12878"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14259"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14386","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14386","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:31:56Z","timestamp":1767609116000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/head.14386"],"URL":"https:\/\/doi.org\/10.1111\/head.14386","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"2022-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}